Dipyridamole
生产企业:App pharmaceuticals llc, Baxter healthcare corp anesthesia and critical care,另有 16 家
Dipyridamole is a phosphodiesterase inhibitor used to prevent postoperative thromboembolic events.
Dipyridamole is a phosphodiesterase inhibitor used to prevent postoperative thromboembolic events.
Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.
For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
共 5 项相关疾病
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。